# Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

> **NCT04957160** · — · COMPLETED · sponsor: **Ipsen** · enrollment: 281 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma (aRCC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04957160
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-09
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04957160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04957160, "Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04957160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*